Ensysce 10-Q: $29.7M Cash, $82.3M Q3 Loss, Going-Concern Warning and MHRA Setback on CY200
ENSC sits 68% above its 52-week low of $0.23.
Summary
Ensysce ended Q3 with $29.7 million in cash after the Series C PIPE and Cy acquisition, but the 10-Q carries a going-concern warning with runway only into the second half of 2027 and discloses that UK regulators have not yet approved the CY200 Phase 2a application.
Key Events · Earnings and Guidance · ENSC
-
Q3 Loss Dominated by Non-Cash IPR&D Charge
Net loss was $82.3 million for the quarter, including a $79.9 million non-cash charge for acquired in-process R&D (primarily CY200) from the Cy Biopharma asset acquisition; operating cash use for nine months was $6.9 million.
-
Cash at $29.7M After PIPE and Cy Deal
Cash and equivalents were $29.7 million at September 30, 2026 versus $4.3 million at December 31, 2025, reflecting $19.6 million of net Series C PIPE proceeds and $11.4 million of net cash acquired from Cy.
-
Going-Concern Doubt Persists
The 10-Q states substantial doubt about the ability to continue as a going concern for 12 months and that existing cash funds planned operations only into the second half of 2027 without additional financing.
-
MHRA Has Not Approved CY200 Phase 2a
On November 6, 2026 the MHRA and the reviewing research ethics committee said the CYBIO 001 application was not approved yet and requested further information, which the company intends to provide.
Analysis · ENSC · Life Sciences
The headline loss is mostly accounting: $79.9 million of the $82.3 million quarterly net loss is a one-time non-cash charge for acquired in-process R&D (CY200) from the Cy Biopharma asset acquisition, so operating cash burn was only $6.9 million for nine months. What matters is the balance sheet and the clock. Cash stands at $29.7 million after $19.6 million of net PIPE proceeds and $11.4 million of net cash acquired with Cy, but management still states substantial doubt about continuing as a going concern and says existing cash funds planned operations only into the second half of 2027 without new financing. Layered on top, the UK regulator told the company on November 6, 2026 that the CY200 Phase 2a application was not approved yet and asked for more information — a delay to the lead program that the $79.9 million write-up was premised on. The company also discloses that shares reserved for future issuance (360.2 million, almost all from the 358.3 million Series C conversion) exceed its 250 million authorized shares, which is why the December 14 proxy seeks a reverse split and an increase to 500 million authorized.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSC was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.23 to $2.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.